Loading stock data…
ALEC
$1.63-0.01 (-0.61%)
After Hours$1.63+0.00 (+0.00%)· Last close Jun 9
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Alector, Inc. in the Healthcare sector is trading at $1.63 with a market capitalization of $240M. Wall Street consensus targets $3.10 (5 analysts), implying a +90.2% move over the next 12 months. The stock is currently 52% below its 52-week high of $3.40, remaining 22.4% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 21 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +90.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 21) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$1.63
Potential Downside
0%
Whystock Fair Value$1.63
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treatin...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$239.81M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.65
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1207.74%
Volume
Today's trading volume
432,074
Recent News
How The Alector (ALEC) Investment Story Is Shifting With Tau Readthroughs And BBB Shuttle Focus
Alector’s updated analyst framework now points to a fair value move from US$2.88 to US$3.10, a modest shift that still signals a meaningful recalibration of expectations. This change is closely tied to how analysts are weighing CELIA’s readthrough for tau-targeting therapies and Alector’s pivot toward blood brain barrier shuttle based designs, balancing the scientific promise against execution risks and the memory of prior trial setbacks. As you read on, you will see how to track these moving...
Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates
Alector (ALEC) delivered earnings and revenue surprises of +40.00% and -65.13%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alkermes (ALKS) Reports Q1 Loss, Beats Revenue Estimates
Alkermes (ALKS) delivered earnings and revenue surprises of +30.31% and +9.50%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
GSK Juggles Alzheimer’s Setback And Leadership Shift With Product Progress
GSK (LSE:GSK) and Alector have discontinued their phase 2 trial of an Alzheimer's drug candidate after the study did not meet efficacy goals. The decision effectively ends a high profile collaboration in neurodegenerative research between the two companies. Separately, GSK received UK approval for Lynavoy (linerixibat) to treat primary biliary cholangitis. The company has also appointed Roanne Parry as Chief People Officer, a move that may shape its global people and culture agenda. GSK,...